NCT01562041View on ClinicalTrials.gov

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 9, 2012

Primary Completion Date

January 2, 2014

Study Completion Date

January 2, 2014

Conditions
Atherosclerotic Coronary Vascular Disease
Interventions
DRUG

Ranolazine 500 mg

Ranolazine 500 mg, oral tablet, b.i.d.

Trial Locations (2)

10021

Novartis Investigative Site, New York

32216

Novartis Investigative Site, Jacksonville

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT01562041 - Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease | Biotech Hunter | Biotech Hunter